Back

Predictors of echocardiographic global longitudinal strain decrease after breast cancer treatment

13 May 2024 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in special populations - cardio-oncology 2 Cardio-Oncology HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Agata Magdalena Bielecka-Dabrowa

Medical University of Lodz, Lodz (Poland)

6 More presentations in this session

Presentation thumbnail
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments
Doctor U. Attanasio (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Predictors of subclinical left ventricular dysfunction after breast cancer radiation therapy when the global longitudinal strain is not available
Doctor A. Stevanovic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Prescreening for cardiac amiloidosis by bone scintigraphy in a population of cancer survivals with left ventricular hypertrophy
Doctor M. Dominique Joseph (Port-au-Prince, HT)
Abstract Slides Video
Presentation thumbnail
The breast cancer chemotherapy influence negatively exercise tolerance assessed in CPET three months after treatment
Professor A. Bielecka-Dabrowa (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Echocardiographic parameters as predictors of prognosis in cardiac amyloidosis: a systematic review and meta-analysis
Doctor N. Sari (Jakarta, ID)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in special populations - cardio-oncology 2

The Event

Event poster

Heart Failure 2024

13 May 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Global longitudinal strain evolution after cancer treatment in breast cancer females
thumbnail
Congress Presentation
Normal left ventricular ejection fraction and impaired longitudinal strain: is this significant cardiotoxicity? - what do the guidelines say?
thumbnail
Congress Presentation
Natriuretic peptides may be suitable for screening long-term heart failure risk in breast cancer survivors after cardiotoxic chemotherapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources